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Endemic brucellar epididymo-orchitis: 
a lo-year experience 
Athanasios G. Papatsoris,(l) Filitsa A. Mpadra,c2) Michalis V. Karamouzis(3) 
and Christos Y. Frangidesc4) 
Objective: To present epidemiologic, clinical and laboratory features, treatment and outcome of patients suffering 
from Brucella melitensis-induced epididymo-orchitis, in comparison with cases of nonspecific epididymo-orchitis. 
Distinction between these two entities is essential, as treatment and outcome are entirely different. 
Methods: In this retrospective study, records of 17 patients serologically diagnosed as suffering from B. mefitensis 
epididymo-orchitis were reviewed in comparison with 141 cases of non-Brucella epididymo-orchitis. All patients 
presented consecutively at a tertiary hospital in southwestern Greece, from 1991 to 2000. Statistical analysis was 
performed using the chi-square test. 
Results: B. melitensis epididymo-orchitis differed from nonspecific epididymo-orchitis, due to its high occupational 
risk, seasonal pattern, gradual onset (P<O.Ol), longer duration, typical undulatory fever (PcO.05) absence of serious 
leukocytosis (PcO.05) and lower urinary tract symptoms, and relatively minimal local signs of florid inflammation 
(PcO.01). Oral medication with doxycycline and rifampicin for 6 weeks was effective, and no relapses or serious side 
effects were recorded during the follow-up period. 
Conclusions: B. melitensis-induced epididymo-orchitis is a recognized clinical problem in endemic regions, requiring 
early detection and appropriate medication. Clinicians encountering epididymo-orchitis should consider the likelihood 
of brucellosis and initiate anti-Brucella medication upon clinical diagnosis and not only after serologic confirmation. 
Int J Infect Dis 2002; 6: 309-313 
INTRODUCTION 
Brucellosis (also known as Mediterranean or Malta 
fever) is a worldwide zoonosis of domestic and wild 
animals which accounts for considerable human mor- 
bidity and economic losses in endemic regions such 
as Mediterranean countries and the Middle East.1*2 
Recently, new brucellar infections in south and central 
Europe have been reported to be imported from the 
Mediterranean region, and approximately 500 000 new 
cases of brucellosis are reported annually, but it is 
estimated that only 4% of cases are recognized.“,4 The 
disease is caused by Brucella species; the most 
pathogenic is Brucella melitensis, followed by B. abortus, 
B. suis, B. canis, B. ovis, B. neotomae and B. maris, which 
was recently discovered.” 
Brucella is transmitted through the gastrointestinal 
tract after consumption of contaminated meat or milk 
and its products, through direct contact with infected 
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tissues, blood or lymph of infected or injured skin, 
through the respiratory system after inhalation in micro- 
biological laboratories, and through the conjunctivae.6,7 
The highest prevalence of brucellosis appears in 
slaughterhouse workers, livestock farmers and shepherds 
in rural communities, veterinarians, and people who 
drink unpasteurized milk or consume cheese made from 
it 8.9 
In the majority of cases, diagnosis is made sero- 
logically with the standard tube Brucella agglutination 
test (STA), and a titer of ?1:160 is considered positive.‘” 
False-negative tests due to blocking antibodies (prozone 
phenomenon) are better evaluated with dilutions as 
high as 1:1280. Sensitivity tests for Brucella antibodies 
(radioimmunoassay (RIA) and enzyme immunoassay 
(ELISA)) are now available and automated.‘i Random 
amplification of polymorphic DNA (RAPD) is also 
a simple, quick and sensitive diagnostic technique.12 
Recently, the PCR assay has been proposed for the 
diagnosis of focal complications of brucellosis.‘3 Blood 
cultures are usually positive in 2 or 3 weeks in about 
50% of patients with acute brucellosis, while bone 
marrow cultures are often positive when blood cultures 
are negative.i4,is 
The symptoms of brucellosis are nonspecific, con- 
sisting of undulatory fever, night sweats, malaise and 
weight 10~s.~ Differential diagnosis includes other acute 
febrile diseases, such as influenza, tularemia, Q fever, 
mononucleosis and enteric fever, while in its chronic 
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form brucellosis resembles tuberculosis, Hodgkin’s 
disease, malaria, HIV infection, histoplasmosis and 
coccioidomycosis4 The most frequent complications are 
bone and joint lesions (e.g. spondylitis and suppurative 
arthritis), hepatosplenomegaly, lymphadenopathy, endo- 
carditis and meningoencephalitis. Overall, the complica- 
tions of brucellosis are attributed to the involvement of 
many systems. 
Genitourinary involvement (epididymo-orchitis, 
prostatitis, cystitis, interstitial nephritis, pyelonephritis, 
IgA nephropathy, exudative glomerulonephritis and 
renal abscess) is usually reported in 240% of patients 
suffering from brucellosis. l6 Brucellar epididymo-orchitis 
is an uncommon cause of localized infection of the testis 
and epididymis, and occurs in about 2-14% of all patients 
with brucellosis as a result of urine Brucella removal or 
as a blood-borne septic metastasis.17-24 
In the present study, we retrospectively analyzed 
the epidemiologic, clinical and laboratory findings, 
treatment and outcome of epididymo-orchitis due to 
B. melitensis infection, in comparison with nonspecific 
epididymo-orchitis, in southwestern Greece. 
METHODS 
One hundred and fifty-eight consecutive patients, aged 
17-72 years (mean age: 43.47 years), diagnosed as 
suffering from epididymo-orchitis, were enrolled in this 
retrospective study, conducted from January 1991 to 
December 2000, in ‘St Andrews’ Patras Regional 
Hospital. We studied the characteristics of B. melitensis- 
induced epididymo-orchitis in comparison with non- 
Brucella epididymo-orchitis, in order to establish clinical 
and laboratory criteria for each group. The serology 
test used was the microtiter agglutination procedure, 
utilizing B. abortus and B. melitensis antigens (Wellcome 
Diagnostics, Dartford, UK). A titer of 1:160 or more was 
interpreted as evidence of Brucella infection, and in 
these patients three blood cultures were performed. 
Both groups were compared in terms of demographic 
characteristics, seasonal pattern, symptom onset, dura- 
tion of illness, pattern of fever, associated lower tract 
symptoms, testicular versus epididymal involvement, 
urine analysis and culture, leukocyte count, erythrocyte 
sedimentation rate (ESR), sonographic appearance, 
response to treatment, and outcome, during a 6-24-month 
follow-up period. 
Statistical analysis was performed using the chi- 
square test, and a P-value of 10.05 was denoted as 
statistically significant. 
RESULTS 
Laboratory diagnosis of brucellosis 
Seventeen of the 158 patients (11%) were diagnosed as 
suffering from B. melitensis epididymo-orchitis, accord- 
ing to their STA titers. In particular, nine patients (53%) 
had titers of 1:640, four (23%) had titers of 1:1280, two 
(12%) had titers of 1:320, and two (12%) had titers of 
1:160. Moreover, in nine of these 17 patients (53%), B. 
melitensis was isolated on blood cultures. 
Patient epidemiologic and clinical characteristics 
The mean age of patients with brucellar epididymo- 
orchitis was 30.15 years (range: 18-67 years), while 
the mean age in the nonspecific group was 44.91 years 
(range: 17-71 years). All patients in the brucellar infect- 
ion group had a high occupational risk for brucellosis, as 
they were livestock farmers and shepherds from rural 
regions, and eight of them (47%) reported drinking un- 
pasteurized milk and/or consuming cheese made from it. 
Furthermore, the disease showed a well-defined seasonal 
pattern, as most cases occurred in spring (41%) and 
summer (29%). In contrast, no particular occupation or 
regional or seasonal pattern was predominant in the 
nonspecific group. 
The onset of epididymo-orchitis was insidious in 15 
of the 17 patients (88%) with brucellosis and acute in 
two patients (12%). In the nonspecific group, the onset 
was acute in 119 patients (84%) and insidious in 22 
patients (16%). 
In the brucellar infection group, 13 of the 17 patients 
(76%) had fever which was typically undulatory. On the 
other hand, 132 of the 141 patients (94%) with non- 
specific epididymo-orchitis had high fever (>38.5”C), 
until appropriate antibiotics were administered (PcO.05). 
Only four patients (23%) suffering from brucellar 
epididymo-orchitis complained of slight burning mictu- 
rition or dysuria, while 118 patients (84%) in the non- 
specific group reported urinary frequency, burning 
micturition and urethral pain (PcO.01). 
Seven of the 17 patients (41%) with brucellar 
infection had unilateral epididymal enlargement which 
was slightly tender, while the other 10 patients (59%) 
had both unilateral epididymal and testicular enlarge- 
ment which was also slightly tender. Moreover, in 13 
patients (76%) in this group, signs of florid inflammation 
were absent in the scrotal skin. In the nonspecific group, 
all patients had both epididymal and testicular enlarge- 
ment, unilateral in 110 (78%) patients and bilateral in 
the remaining 31 patients (22%). In all patients of this 
group, scrotal tenderness was moderate to extreme and 
the scrotal skin showed extensive redness, edema and 
heat (PcO.01). 
Laboratory investigations 
Eleven of the 17 patients (65%) in the brucellar in- 
fection group had normal urine analysis and culture, 
while the remaining six patients (35%) had mild pyuria 
with negative culture for common microorganisms 
(aseptic pyuria). In contrast, in the other group all 
patients had mild to severe pyuria, and a variety of 
pathogens were grown on culture: Escherichia coli 
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(52%), Proteus mirabilis (17%), Klebsiella pneumoniae 
(9%), enterococci (9%), Staphylococcus aureus (8%), 
Serratia (2%), Pseudomonas aeruginosa (2%) and 
Acinetobacter (1%). 
In the brucellar infection group, only six patients 
(35%) had mild leukocytosis, up to 12x103/mm3 with 
predominant lymphocyte type, while 127 of the patients 
(90%) with nonspecific epididymo-orchitis had leuko- 
cytosis exceeding 12x 103/mm3, usually of polymorpho- 
nuclear type (P<O.O5).The ESR was raised (>30 mm/h) 
in all patients in the nonspecific group and in 13 of the 
17 patients (76%) with brucellar epididymo-orchitis. 
In both groups when the epididymis was involved, 
ultrasound (US) revealed a gross enlargement of the 
body and tail with a markedly heterogeneous echo 
texture. Also, when the testis was involved, the echo 
texture was homogeneous and diffusely hypoechoic, and 
power doppler showed increased vascularity. Thickening 
of the scrotal wall and tunica albuginea was observed in 
128 patients (91%) with nonspecific epididymo-orchitis 
and in seven patients (41%) of the brucellar group. 
Mildly reactive hydrocele was revealed in 36 patients 
(26%) with nonspecific disease and in two patients 
(12%) with brucellar epididymo-orchitis (P>O.O5). 
During the follow-up period, US revealed the develop- 
ment of an intratesticular abscess in eight of 141 patients 
(6%) with nonspecific epididymo-orchitis, and therefore 
orchiectomy was performed. No intratesticular abscess 
was revealed in the brucellar epididymo-orchitis group 
during the follow-up period. 
Treatment and outcome 
All patients with brucellar epididymo-orchitis failed to 
respond to a 3-day empirical treatment with netilmicin 
and a second-generation cephalosporin intravenously, 
which was usually initiated while waiting for serology 
confirmation. In particular, habitual medication was 
initiated in all but four patients, for whom we had a very 
high clinical suspicion for brucellar epididymo-orchitis, 
as they reported personal or family history of brucellosis, 
gradual onset of night sweats and undulatory fever, and 
consumption of raw milk and cheese, and presented 
aseptic pyuria. Improvement of local signs and clinical 
symptoms was observed immediately in these four 
patients and gradually in the remaining 13 patients, 
when specific anti-Brucella medication was administrated; 
an oral combination of doxycycline (200 mg/day) and 
rifampicin (900 mg/day) was applied for a total of 6 
weeks. On the other hand, 133 patients (94%) in the 
nonspecific group showed immediate improvement of 
the urinary tract symptoms and of scrotal enlargement 
and tenderness with empirical treatment, followed by 
appropriate oral medication for 2-3 weeks, according to 
the sensitivity tests. Fever subsided in 4-9 days (mean: 
7.14 days) in patients with brucellar epididymo-orchitis 
and in 2-8 days (mean: 5.85 days) in the nonspecific 
group. The mean hospitalization period was 8.39 days 
(range: 5-10 days) in patients with brucellar epididymo- 
orchitis and 6.21 days (range: 3-9 days) in patients with 
nonspecific epididymo-orchitis. No drop-outs or serious 
medication side effects were reported in either group. 
Furthermore, during the follow-up period, no relapses 
were recorded among the brucellar epididymo-orchitis 
patients, while 15 of 141 patients (11%) in the non- 
specific epididymo-orchitis group relapsed and received 
a new combination of antibiotics. 
DISCUSSION 
Brucellosis remains an important clinical problem 
worldwide, and needs to be highlighted as a continuing 
cause of morbidity in southern Europe and in many 
developing countries. In parallel, epididymo-orchitis is a 
common clinical entity in medical practice, and inappro- 
priate management may result in serious complications 
such as testicular abscess, atrophy and male infertility.25 
Although brucellosis was first reported in 1859 by 
Marston, it was not until 1928 that Hardy first described 
a case of brucellar epididymo-orchitis.26 
Clinical manifestations and laboratory tests for 
brucellosis are usually used for the diagnosis of brucellar 
epididymo-orchitis. Furthermore, US (gray-scale and 
power doppler) and nuclear testicular scans may 
differentiate this rare inflammatory entity from 
numerous benign (e.g. torsion, trauma, hematocele) or 
malignant causes of enlarged scrotum.27,28 Also, US 
during the follow-up period is useful for the early 
detection of a developing intratesticular abscess.29 
High clinical suspicion for brucellar epididymo-orchitis 
together with the above imaging diagnostic tools con- 
tribute to the reduction of unnecessary orchiectomies, 
especially in cases of failure of empirical antibiotic 
therapy.30 
Our results show that B. melitensis-induced 
epididymo-orchitis can be distinguished from nonspecific 
epididymo-orchitis by a history of contact with animals, 
drinking raw milk or consuming cheese made from it, 
by its seasonal pattern, gradual onset (P<O.Ol), longer 
duration, typical undulatory fever with periods of 
apyrexia (P<O.O5), minimal local features of florid 
inflammation (P<O.Ol), and absence of lower urinary 
tract symptoms and of serious leukocytosis (PcO.05). 
Moreover, we observed that blood cultures were positive 
for Brucella in 53% of cases, no severe blood leuko- 
cytosis was present, and urine analysis was normal in the 
majority of the patients. The above-mentioned criteria 
justified termination of empirical antibiotic therapy and 
initiation of oral anti-Brucella treatment with doxycycline 
(200 mg/day) and rifampicin (900 mg/day) for at least 6 
weeks, resulting in complete resolution in all patients 
with brucellar epididymo-orchitis, without any drop- 
outs, serious side effects, or relapses. It is noteworthy 
that, in cases of high clinical suspicion for Brucella 
etiology, specific anti-Brucella medication was initiated 
while awaiting serology confirmation. According to 
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the current literature, alternative effective therapeutic 
regimens consist of streptomycin intramuscularly and 
tetracycline, with or without cotrimoxazole, orally.3l 
Fortunately, no increase in resistance to anti-Bruce& 
medication has been reported in studies conducted in 
endemic regions. 32 Furthermore, it must be mentioned 
that single-drug regimens are not recommended because 
relapse rates may be as high as 50% and might trigger a 
new episode of systemic brucellosis.33 
In the present study, all patients with B. melitensis 
epididymo-orchitis were livestock farmers and shepherds 
from rural regions, and 47% of them reported drinking 
unpasteurized milk or consuming cheese made from 
it. Hence, the risk of acquiring brucellosis might be 
decreased by avoiding consumption of raw milk and 
products, guarding against exposure to tissues from 
infected animals, and protecting potential portals of 
entry in high-risk individuals with appropriate clothing. 
Unfortunately, brucellosis is still a public health problem 
in countries where the infection has not been eradicated 
from the animal hosts.’ In Greece, the necessity of 
medical prophylactic measures and the strict application 
of sanitary measures has been outlined since the early 
1970~.~~ Efficient control of the disease in domesticated 
livestock is proposed as one of the most effective 
means of preventing human contamination. This might 
be accomplished by immunizing animals with a live 
attenuated Brucella vaccine, such as the B. abortus strain 
B.51.35,36 Moreover, rapid DNA-based diagnostic tests 
for both humans and livestock are continuouly improv- 
ing. Also, the first complete Brucella genome sequence 
will be released soon, contributing to the development 
of novel prophylactic and therapeutic strategies.l 
In conclusion, B. melitensis-induced epididymo- 
orchitis is a recognized clinical problem in endemic 
regions such as southwestern Greece. Clinicians should 
consider brucellar infection in patients presenting with 
enlarged scrotum and initiate anti-Brucella medication 
upon clinical diagnosis and not only after serologic con- 
firmation. The outcome is usually favorable, provided 
that appropriate medication is applied in adequate 
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